CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma

Molecular Therapy

Volumn 25, Issue 9, 2017, Pages 2214-2224

  Heczey, Andras ^a   Louis, Chrystal U ^a   Savoldo, Barbara ^b   Dakhova, Olga ^c   Durett, April ^c   Grilley, Bambi ^c   Liu, Hao ^a   Wu, Mengfeng F ^a   Mei, Zhuyong ^c   Gee, Adrian ^c   Mehta, Birju ^c   Zhang, Huimin ^c   Mahmood, Nadia ^a   Tashiro, Haruko ^c   Heslop, Helen E ^c   Dotti, Gianpietro ^b   Rooney, Cliona M ^c   Brenner, Malcolm K ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

GD2 CAR; immunotherapy; neuroblastoma

Indexed keywords

CD11B ANTIGEN; CD163 ANTIGEN; CD33 ANTIGEN; CD45 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CYCLOPHOSPHAMIDE; FLUDARABINE; INTERLEUKIN 15; PEMBROLIZUMAB; CYTOKINE; FUSION PROTEIN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; LYMPHOCYTE ANTIGEN RECEPTOR; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ABDOMINAL PAIN; ADULT; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BACKACHE; BONE MARROW CELL; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CELL EXPANSION; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CYTOKINE RELEASE SYNDROME; DRUG SAFETY; FACE PAIN; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN CELL; INHIBITION KINETICS; LEUKOPENIA; LIMB PAIN; LYMPH NODE PAIN; LYMPHOCYTOPENIA; MALE; NECK PAIN; NEUROBLASTOMA; NEUTROPENIA; PARESTHESIA; PELVIC PAIN; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; SCHOOL CHILD; T CELL DEPLETION; THROMBOCYTOPENIA; TREATMENT RESPONSE; YOUNG ADULT; ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; ANTAGONISTS AND INHIBITORS; BLOOD; GENETICS; IMMUNOLOGY; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; T LYMPHOCYTE; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COMBINED MODALITY THERAPY; CYTOKINES; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MALE; MOLECULAR TARGETED THERAPY; MYELOID CELLS; NEUROBLASTOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85020269949     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2017.05.012     Document Type: Article

References (43)

1. Yu, A.L., Gilman, A.L., Ozkaynak, M.F., London, W.B., Kreissman, S.G., Chen, H.X., Smith, M., Anderson, B., Villablanca, J.G., Matthay, K.K., et al., Children's Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363 (2010), 1324–1334.
2. Cheung, N.K., Cheung, I.Y., Kushner, B.H., Ostrovnaya, I., Chamberlain, E., Kramer, K., Modak, S., Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J. Clin. Oncol. 30 (2012), 3264–3270.
3. Pule, M.A., Savoldo, B., Myers, G.D., Rossig, C., Russell, H.V., Dotti, G., Huls, M.H., Liu, E., Gee, A.P., Mei, Z., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14 (2008), 1264–1270.
4. Dotti, G., Gottschalk, S., Savoldo, B., Brenner, M.K., Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol. Rev. 257 (2014), 107–126.
5. Rouce, R.H., Sharma, S., Huynh, M., Heslop, H.E., Recent advances in T-cell immunotherapy for haematological malignancies. Br. J. Haematol. 176 (2017), 688–704.
6. Louis, C.U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G.D., Rossig, C., Russell, H.V., Diouf, O., Liu, E., et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118 (2011), 6050–6056.
7. Pulè, M.A., Straathof, K.C., Dotti, G., Heslop, H.E., Rooney, C.M., Brenner, M.K., A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol. Ther. 12 (2005), 933–941.
8. Turtle, C.J., Hanafi, L.A., Berger, C., Gooley, T.A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T.M., et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126 (2016), 2123–2138.
9. John, L.B., Devaud, C., Duong, C.P., Yong, C.S., Beavis, P.A., Haynes, N.M., Chow, M.T., Smyth, M.J., Kershaw, M.H., Darcy, P.K., Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin. Cancer Res. 19 (2013), 5636–5646.
10. Brodeur, G.M., Pritchard, J., Berthold, F., Carlsen, N.L., Castel, V., Castelberry, R.P., De Bernardi, B., Evans, A.E., Favrot, M., Hedborg, F., et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol. 11 (1993), 1466–1477.
11. Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371 (2014), 1507–1517.
12. Davila, M.L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S.S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med., 6, 2014, 224ra25.
13. Murphy, K., Travers, P., Walport, M., Janeway, C., Janeway's Immunobiology. 2012, Garland Science.
14. Airoldi, I., Lualdi, S., Bruno, S., Raffaghello, L., Occhino, M., Gambini, C., Pistoia, V., Corrias, M.V., Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L. Br. J. Cancer 88 (2003), 1527–1536.
15. Asgharzadeh, S., Salo, J.A., Ji, L., Oberthuer, A., Fischer, M., Berthold, F., Hadjidaniel, M., Liu, C.W., Metelitsa, L.S., Pique-Regi, R., et al. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J. Clin. Oncol. 30 (2012), 3525–3532.
16. Svennerholm, L., Boström, K., Fredman, P., Jungbjer, B., Månsson, J.E., Rynmark, B.M., Membrane lipids of human peripheral nerve and spinal cord. Biochim. Biophys. Acta 1128 (1992), 1–7.
17. Sorkin, L.S., Otto, M., Baldwin, W.M. 3rd, Vail, E., Gillies, S.D., Handgretinger, R., Barfield, R.C., Ming Yu, H., Yu, A.L., Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia. Pain 149 (2010), 135–142.
18. Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A.G., Grilley, B., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365 (2011), 1673–1683.
19. Dudley, M.E., Yang, J.C., Sherry, R., Hughes, M.S., Royal, R., Kammula, U., Robbins, P.F., Huang, J., Citrin, D.E., Leitman, S.F., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26 (2008), 5233–5239.
20. Muranski, P., Boni, A., Wrzesinski, C., Citrin, D.E., Rosenberg, S.A., Childs, R., Restifo, N.P., Increased intensity lymphodepletion and adoptive immunotherapy–how far can we go?. Nat. Clin. Pract. Oncol. 3 (2006), 668–681.
21. Dudley, M.E., Wunderlich, J., Nishimura, M.I., Yu, D., Yang, J.C., Topalian, S.L., Schwartzentruber, D.J., Hwu, P., Marincola, F.M., Sherry, R., et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Immunother. 24 (2001), 363–373.
22. Anthony, S.M., Rivas, S.C., Colpitts, S.L., Howard, M.E., Stonier, S.W., Schluns, K.S., Inflammatory signals regulate IL-15 in response to lymphodepletion. J. Immunol. 196 (2016), 4544–4552.
23. Gattinoni, L., Finkelstein, S.E., Klebanoff, C.A., Antony, P.A., Palmer, D.C., Spiess, P.J., Hwang, L.N., Yu, Z., Wrzesinski, C., Heimann, D.M., et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202 (2005), 907–912.
24. Xu, Y., Zhang, M., Ramos, C.A., Durett, A., Liu, E., Dakhova, O., Liu, H., Creighton, C.J., Gee, A.P., Heslop, H.E., et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123 (2014), 3750–3759.
25. Long, A.H., Haso, W.M., Shern, J.F., Wanhainen, K.M., Murgai, M., Ingaramo, M., Smith, J.P., Walker, A.J., Kohler, M.E., Venkateshwara, V.R., et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21 (2015), 581–590.
26. Conlon, K.C., Lugli, E., Welles, H.C., Rosenberg, S.A., Fojo, A.T., Morris, J.C., Fleisher, T.A., Dubois, S.P., Perera, L.P., Stewart, D.M., et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol. 33 (2015), 74–82.
27. Rhode, P.R., Egan, J.O., Xu, W., Hong, H., Webb, G.M., Chen, X., Liu, B., Zhu, X., Wen, J., You, L., et al. Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models. Cancer Immunol. Res. 4 (2016), 49–60.
28. Vincent, M., Bessard, A., Cochonneau, D., Teppaz, G., Solé, V., Maillasson, M., Birklé, S., Garrigue-Antar, L., Quéméner, A., Jacques, Y., Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency. Int. J. Cancer 133 (2013), 757–765.
29. Gargett, T., Yu, W., Dotti, G., Yvon, E.S., Christo, S.N., Hayball, J.D., Lewis, I.D., Brenner, M.K., Brown, M.P., GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. Mol. Ther. 24 (2016), 1135–1149.
30. John, L.B., Kershaw, M.H., Darcy, P.K., Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. OncoImmunology, 2, 2013, e26286.
31. Cherkassky, L., Morello, A., Villena-Vargas, J., Feng, Y., Dimitrov, D.S., Jones, D.R., Sadelain, M., Adusumilli, P.S., Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J. Clin. Invest. 126 (2016), 3130–3144.
32. Chong, E.A., Melenhorst, J.J., Lacey, S.F., Ambrose, D.E., Gonzalez, V., Levine, B.L., June, C.H., Schuster, S.J., PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood 129 (2017), 1039–1041.
33. Arina, A., Bronte, V., Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells. Curr. Opin. Immunol. 33 (2015), 120–125.
34. Ostrand-Rosenberg, S., Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol. Immunother. 59 (2010), 1593–1600.
35. Long, A.H., Highfill, S.L., Cui, Y., Smith, J.P., Walker, A.J., Ramakrishna, S., El-Etriby, R., Galli, S., Tsokos, M.G., Orentas, R.J., Mackall, C.L., Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas. Cancer Immunol. Res. 4 (2016), 869–880.
36. Ugel, S., De Sanctis, F., Mandruzzato, S., Bronte, V., Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J. Clin. Invest. 125 (2015), 3365–3376.
37. Song, L., Asgharzadeh, S., Salo, J., Engell, K., Wu, H.W., Sposto, R., Ara, T., Silverman, A.M., DeClerck, Y.A., Seeger, R.C., Metelitsa, L.S., Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J. Clin. Invest. 119 (2009), 1524–1536.
38. Santilli, G., Piotrowska, I., Cantilena, S., Chayka, O., D'Alicarnasso, M., Morgenstern, D.A., Himoudi, N., Pearson, K., Anderson, J., Thrasher, A.J., Sala, A., Polyphenon E enhances the antitumor immune response in neuroblastoma by inactivating myeloid suppressor cells. Clin. Cancer Res. 19 (2013), 1116–1125.
39. Heczey, A., Liu, D., Tian, G., Courtney, A.N., Wei, J., Marinova, E., Gao, X., Guo, L., Yvon, E., Hicks, J., et al. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood 124 (2014), 2824–2833.
40. Künkele, A., Johnson, A.J., Rolczynski, L.S., Chang, C.A., Hoglund, V., Kelly-Spratt, K.S., Jensen, M.C., Functional tuning of CARs reveals signaling threshold above which CD8+ CTL antitumor potency is attenuated due to cell Fas-FasL-dependent AICD. Cancer Immunol. Res. 3 (2015), 368–379.
41. Li, W., Guo, L., Rathi, P., Marinova, E., Gao, X., Wu, M.F., Liu, H., Dotti, G., Gottschalk, S., Metelitsa, L.S., Heczey, A., Redirecting T cells to glypican-3 with 4-1BB zeta chimeric antigen receptors results in Th1 polarization and potent antitumor activity. Hum Gene Ther. 28 (2017), 437–448.
42. Rossig, C., Bollard, C.M., Nuchtern, J.G., Rooney, C.M., Brenner, M.K., Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 99 (2002), 2009–2016.
43. Yanik, G.A., Parisi, M.T., Shulkin, B.L., Naranjo, A., Kreissman, S.G., London, W.B., Villablanca, J.G., Maris, J.M., Park, J.R., Cohn, S.L., et al. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the children's oncology group. J. Nucl. Med. 54 (2013), 541–548.